Orecil NF

Quick links to important sections

Orecil NF

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orecil NF

Property Description
Active Ingredients Hydrocortisone, Ofloxacin, Lidocaine Hydrochloride
Form Otic solution or suspension (Ear drops)
Pharmacological Class Combination of Corticosteroid, Antibiotic, and Local Anesthetic
General Purpose To address localized ear inflammation, pain, and bacterial infection
Origin Synthetic

Composition and Classification of Orecil NF

Orecil NF is defined as a specialized, fixed-dose combination drug formulated as an otic preparation, which means it is a solution or suspension designed specifically for administration into the external ear canal. The preparation integrates three distinct, synthetic active compounds: Hydrocortisone, a potent corticosteroid; Ofloxacin, a Fluoroquinolone Antibiotic; and Lidocaine Hydrochloride, a recognized Local Anesthetic. This strategic combination, often manufactured by companies such as Finecure Pharmaceuticals, is differentiated by its three-pronged approach targeting symptoms and microbial causes simultaneously. Ofloxacin, for example, is clinically recognized for its efficacy against a wide spectrum of bacteria. This confirmed antibiotic component is used to eliminate microbial causes of the condition. Hydrocortisone contributes anti-inflammatory properties, while Lidocaine provides the necessary rapid numbing action for pain relief.

What is the General Purpose of this Combination?

The general purpose of combining these three components is to provide a comprehensive, multi-component response to localized external ear conditions. This structure allows the preparation to efficiently mitigate the key factors contributing to patient distress. The combination of an anti-inflammatory agent with an antibiotic and an anesthetic in otic preparations is a medically recognized strategy for managing both the infection and the severe discomfort associated with inflammation. This approach is designed to hasten comfort by tackling both the distressful symptoms and the root cause. The formulation strategically unites agents to suppress inflammation, alleviate discomfort, and target bacterial sources, promoting the restoration of local comfort and health in the ear canal.

Regulatory References

  1. Neomycin, Polymyxin, and Hydrocortisone Otic | MedlinePlus

What side effects are possible with Orecil NF?

Possible Side Effects and Safety Information

The safety profile for this otic combination preparation is derived from official regulatory documentation and reflects adverse events categorized by frequency and system-organ class.

Officially Documented Adverse Reactions

Adverse reactions are classified according to incidence observed in clinical studies and post-marketing reports for the active components, primarily Ofloxacin.

Classification Example Reactions (System Organ Class)
Application Site (1%–17%) Burning, stinging, pruritus (itching), local irritation.
Common (1%–10%) Taste perversion (Gastrointestinal), dizziness (Nervous System), earache (Ear and Labyrinth), rash (Skin).
Uncommon (0.1%–1%) Otalgia (ear pain), otorrhagia (ear bleeding), vertigo, fever.

Regulatory Safety Considerations

The most clinically significant safety pattern documented is the risk of Severe Hypersensitivity (Anaphylactic) Reactions associated with the fluoroquinolone drug class. This may involve cardiovascular collapse, angioedema, and airway obstruction, even when administered locally.

Contraindications define situations where the medicine should not be used, including a history of hypersensitivity to any quinolone or component of the preparation, or the presence of viral infections of the ear. The use of certain components is generally restricted in the presence of a perforated eardrum.

Time-Related Patterns indicate that prolonged use of the anti-infective component may result in the overgrowth of non-susceptible organisms, such as fungi (Superinfection).

Population Safety Notes address specific groups. For example, Ofloxacin is classified as Pregnancy Category C by the FDA, and regulatory caution is noted regarding the potential for serious adverse reactions in nursing infants due to the quinolone component.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

The regulatory documentation describes the overdose profile for Orecil NF primarily through the potential for systemic absorption of its active components, particularly following accidental ingestion of the otic solution.

Overdose manifestations related to the Lidocaine component may initially present as CNS signs, including tremor, tinnitus, disorientation, and tingling of the tongue and lips. More severe systemic toxicity can rapidly progress to seizures, CNS depression, cardiovascular collapse, and respiratory arrest, which can be fatal. Prolonged or excessive use may lead to systemic corticosteroid effects, such as HPA axis suppression or signs resembling Cushing's syndrome.

Regulator-Mandated Emergency Actions

Immediate medical attention, or contact with a Poison Help line, is required if the otic solution is accidentally swallowed. Urgent emergency treatment is also mandated for any signs of acute systemic toxicity or severe hypersensitivity reactions, which include anaphylaxis, airway obstruction, and loss of consciousness.

There is no specific antidote known for the systemic toxicity of the local anesthetic component. Management involves supportive and resuscitative measures, including airway management and close monitoring. Pediatric patients and individuals with severe hepatic or renal disease are officially noted to be at a heightened risk for severe toxicity.

Therapeutic Uses of Orecil NF

What Orecil NF Treats: Main Uses and Benefits

The Orecil NF otic preparation is applied in clinical settings that involve acute or unstable symptom patterns associated with infection, localized inflammation, and pain. It is primarily used for managing conditions characterized by periods of heightened symptoms that cluster into patterns requiring supportive management.

The antibiotic component is commonly used to address conditions like Acute Otitis Externa (Swimmer’s ear) and Acute Otitis Media in pediatric patients with tympanostomy tubes. The key conditions it helps manage are conditions presenting with systemic or localized discomfort, acute otitis externa, and conditions involving inflammatory or irritative processes.

Quick Fact: Relief for Acute Otalgia

The combination is commonly used to help with symptoms related to physical discomfort, and is relevant for easing pronounced ear pain (otalgia) and localized swelling. This supports general well-being during symptomatic phases and helps address symptoms that create noticeable physiological strain.

Regulatory References

  1. NIH DailyMed label for Ofloxacin Otic Solution

Eligibility and Restrictions for Use

Who can and cannot use Orecil NF?

Eligibility to use Orecil NF, a combination otic solution containing Hydrocortisone, Ofloxacin, and Lidocaine Hydrochloride, is determined by strict rules outlined in regulatory labeling, focusing on patient age and specific pre-existing conditions.


Populations Who Must Not Use (Contraindicated)

Use is absolutely contraindicated for patients with a known hypersensitivity or allergy to ofloxacin, other fluoroquinolone antibiotics, hydrocortisone, lidocaine, or any other ingredient in the formulation. Due to the presence of the corticosteroid (Hydrocortisone), the medicine is also prohibited for individuals with viral infections (e.g., Herpes simplex) or fungal diseases of the external ear canal.


Age and Condition Restrictions

The medicine's use is not established in infants under six months of age. For children, the minimum approved age is typically six months for Acute Otitis Media with tubes, and one year for Acute Otitis Externa, as defined by the Ofloxacin component's established safety data. Use during pregnancy and breastfeeding is considered conditional, requiring caution and professional risk-benefit assessment. Patients with a known or suspected perforated eardrum may also have restricted use, unless specifically indicated for a condition where the drum is compromised.

What should I know about interactions with other medicines?

Orecil NF Interactions with other medicines and products

The interaction profile for Orecil NF is primarily based on the documented systemic risks of its active components—Ofloxacin, Hydrocortisone, and Lidocaine Hydrochloride—as specific drug interaction studies have not been conducted with the otic solution itself.

Interaction Domain Official Regulatory Classification/Requirement
Prohibited Combinations Co-administration with certain QT-prolonging drugs (e.g., Pimozide, Dronedarone, Terfenadine) is contraindicated or not recommended with systemic Ofloxacin due to the risk of additive cardiac effects (QTc prolongation).
Pharmacodynamic Risks The concurrent systemic use of a corticosteroid (Hydrocortisone) and a fluoroquinolone (Ofloxacin) is formally noted to increase the risk of tendinitis and tendon rupture.
Absorption Constraints Oral co-administration of Ofloxacin components with polyvalent cation preparations (such as certain antacids or mineral supplements) must be separated by at least 2 to 6 hours to prevent significant reduction in Ofloxacin absorption.
Exposure Modification Abametapir is officially documented to increase the systemic concentration of Lidocaine. Conversely, Ofloxacin is noted to have a low likelihood of significant CYP enzyme interaction with drugs like Theophylline or Warfarin.
Population Notes The systemic effects of Hydrocortisone are noted to be enhanced in patients with cirrhosis or hypothyroidism. Lidocaine's kinetics are altered by impaired liver function, which can lead to increased blood accumulation.

These constraints are drawn from authoritative government labeling and define the limits and restrictions on co-administration for the active ingredients to manage potential interaction risks.

Mechanism of Action

The mechanism of Orecil NF involves the coordinated action of its three components, each targeting a distinct physiological process to contribute to the drug’s observed physiological actions.

Modulation of Inflammatory Signal Cascades

This domain centers on Hydrocortisone's action as an agonist at the intracellular Glucocorticoid Receptors (GRs). Activation of these receptors suppresses genes that produce pro-inflammatory mediators (e.g., prostaglandins and leukotrienes) while promoting anti-inflammatory proteins. This mechanism contributes to lowering localized vascular permeability and the infiltration of inflammatory cells, modulating the magnitude of the physiological response.

Rapid Blockade of Peripheral Nociceptive Signals

Lidocaine employs a mechanism characterized by rapid kinetics by functioning as a blocker of Voltage-Gated Sodium Channels ( Na V Channels) on peripheral sensory nerves. By binding to these channels, Lidocaine prevents the sodium influx required for nerve cell depolarization and action potential generation. This mechanism results in the cessation of local sensory nerve conduction, inhibiting the propagation of the nerve action potential.

Bactericidal Interference with Microbial DNA

The Ofloxacin component exerts a bactericidal effect through the inhibition of essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. The binding of Ofloxacin stabilizes the DNA-enzyme complex, leading to irreparable DNA strand breaks and the rapid arrest of microbial replication. The outcome of this process is the cessation of microbial proliferation.

Dosage and Administration Information

Orecil NF is a prescription-only otic solution, which in some formulations contains active ingredients such as Ofloxacin, Hydrocortisone, and Lidocaine for the treatment of certain ear infections, including otitis externa. It must be administered exactly as prescribed by a healthcare professional.

Administration Steps

  1. Preparation: Hold the bottle in your hand for one to two minutes to gently warm the solution. This step is important to prevent dizziness that can result from instilling a cold solution into the ear canal.
  2. Positioning: The patient should lie down with the affected ear facing upward.
  3. Instillation: Clean any discharge from the outer ear without inserting anything into the canal. Instill the prescribed number of drops into the ear canal. For infections that require the drops to reach the middle ear (e.g., in patients with tympanostomy tubes), the tragus (the small projection in front of the ear canal) may need to be pumped inward four times after instillation to help the medication penetrate.
  4. Retention: Maintain the position with the affected ear facing upward for at least five minutes to allow the medicine to fully penetrate the ear canal.
  5. Completion: Repeat the procedure for the opposite ear, if necessary. Avoid touching the dropper tip to any surface, including the ear, to maintain sterility.

Important Considerations

  • Use this medication for the full duration prescribed, even if symptoms begin to improve quickly, to ensure the infection is completely cleared. Stopping early may lead to a return of the infection.
  • If no improvement is observed after the specified treatment period, consult your physician to review the diagnosis and treatment plan.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Orecil NF

This overview summarizes the structure and nature of the clinical research conducted for Orecil NF otic solution, focusing on the evidence landscape as reported by regulatory and scientific sources. It is not intended to provide medical advice, dosing instructions, or information on side effects.


Evidence for Use in Acute Otitis Externa (AOE)

Acute Otitis Externa (AOE), or Swimmer's Ear, was studied using short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. The research examined outcomes such as the resolution of visible signs, microbiological outcomes related to bacteria, and outcomes related to physical discomfort, like pain relief. These studies included pediatric patients (6 months and older), adolescents, and adults. Findings describe patterns observed over short follow-up periods, typically covering the 7-day course and up to 14 days post-initiation of therapy.


Evidence for Use in Acute Otitis Media with Tympanostomy Tubes (AOMT)

Research for Acute Otitis Media with Tympanostomy Tubes (AOMT) primarily consists of short-term RCTs focusing on the antibiotic component (Ofloxacin) in pediatric patients with ear tubes. These trials research examined outcomes such as the Clinical Success Rate and the Time to Cessation of Otorrhea (ear discharge). The studies report how symptoms evolved during defined time intervals, but provide limited insight into the specific contribution of the corticosteroid and local anesthetic when used in the triple combination for this condition.


The Landscape of Evidence Gaps

Clinical research primarily focuses on short-term symptom patterns. Long-term effects are not fully established, meaning there is limited information regarding the recurrence rate or durability of the response beyond the initial two weeks. Comparative evidence is lacking for the specific triple-combination against dual-combination products or the pain-relieving agent used alone. Furthermore, the results apply only to the populations studied, and data for certain smaller subgroups remain insufficient.

Key Studies & References Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial...

Frequently Asked Questions (FAQ)

Common questions about Orecil NF (FAQ)


Q: Can Orecil NF be taken with common pain relievers?

A: Official product information notes that the active ingredients, Ofloxacin and Lidocaine, have documented interactions with certain other medicines, including some common pain relievers. Regulatory guidance describes the patient’s disclosure of all co-administered medicines to the healthcare provider as a standard requirement for evaluation.


Q: Do I need to change my diet while using Orecil NF?

A: Official interaction information notes that polyvalent cation preparations (found in some supplements or antacids) can affect the Ofloxacin component. Regulatory documents do not typically detail broad dietary changes beyond this specific interaction for the local ear drop solution.


Q: How long does it typically take to see or feel any effect from Orecil NF?

A: Clinical observations for similar ear drop products suggest that patients may begin to notice improvement in symptoms during the first few days of treatment. Official use conditions describe completing the full prescribed course in an effort to fully resolve the infection.


Q: Are there any long-term health risks associated with Orecil NF?

A: Studies and official information indicate that clinical research has primarily focused on the short-term use and effects of this solution. Limited information is currently available to fully establish the potential for long-term health risks.


Q: Can people with liver issues use Orecil NF?

A: Official labeling describes that for the Lidocaine component, the way the body processes the medicine (kinetics) can be altered in patients who have impaired liver function. This is noted as potentially leading to increased systemic accumulation of the ingredient.


Q: Can Orecil NF be used by children?

A: Studies and official information indicate that the safety and effectiveness of the Ofloxacin component have been established in pediatric patients, typically in the age range of 6 months and older. The eligibility for use is determined by the specific ear condition and the age limits outlined in the prescribing information.


Q: What should I know about taking Orecil NF with herbal supplements?

A: Official guidance generally describes the standard requirement for informing a healthcare provider about all prescription, non-prescription, vitamin, and herbal supplements used. This is necessary due to the potential for interactions that may not be fully documented in the product's official labeling.


Q: What is the typical duration of treatment with Orecil NF?

A: Regulatory information describes the typical treatment duration for the ear infections it treats as generally ranging from 7 to 14 days. The duration is always specified by the healthcare provider based on the type and severity of the infection.


Q: Does Orecil NF interact with over-the-counter cold and flu medicines?

A: Official regulatory documents for the active components note potential interactions with certain ingredients commonly found in cold and flu medicines. The official product information generally describes the standard practice of discussing all co-administered products with a healthcare provider.


Q: Is Orecil NF intended for short-term or long-term use?

A: Based on the established dosage regimen and the scope of clinical trials, the medication is described in official documents as being intended for short-term use. The purpose is to treat acute (sudden onset) ear infections over a defined period.


Q: What happens if I miss a dose of Orecil NF?

A: Official administration instructions include specific guidance for managing a missed dose. These guidelines describe when an application may be skipped or immediately performed, with a strict directive to avoid doubling the amount used.


Q: Does Orecil NF interact with alcohol?

A: Official regulatory sources for this localized otic solution generally do not list a known interaction between the product and alcohol.


Q: Why do some people experience fatigue when starting Orecil NF?

A: Fatigue is described as a potential effect in safety documentation, specifically associated with the systemic use of the fluoroquinolone class that Ofloxacin belongs to. This effect is considered rare with the use of the localized otic solution.


Q: Is Orecil NF a habit-forming medicine?

A: According to regulatory agencies, the active ingredients contained within this solution are not classified as controlled substances. Therefore, the medicine is not formally classified as a habit-forming substance.


Q: Can Orecil NF affect sleep?

A: Insomnia (difficulty sleeping) is noted as a potential central nervous system effect associated with the systemic use of the fluoroquinolone class. The patient's discussion of any significant changes in sleep patterns with a healthcare provider is generally described in official documentation.


Q: Is Orecil NF appropriate for older adults?

A: Official regulatory documents note that specific clinical information comparing the use of the Ofloxacin component in older adults versus other age groups is limited. Existing information does note that kinetics may be altered in older patients with liver issues.


Q: Does Orecil NF have any warnings about driving or operating machinery?

A: Official administration instructions warn that if the solution is instilled cold, it can cause dizziness. This means patients should be aware of this potential, temporary effect before engaging in activities like driving or operating machinery immediately after use.


Q: Can Orecil NF be crushed or split?

A: The medicine is formulated as a liquid otic solution (ear drops), not a solid tablet or capsule. Therefore, the concept of crushing or splitting the medicine does not apply to its liquid form.


Q: Is it normal to feel a mild headache when first starting Orecil NF?

A: Headache is described as a possible, though typically rare, side effect in the product labeling for similar otic solutions. Official guidance describes informing a healthcare provider if any symptom persists or causes concern.


Q: Does Orecil NF interact with birth control pills?

A: Regulatory documents for the localized otic solution generally do not list a specific interaction with oral birth control pills.


Q: What is the risk of an allergic reaction to Orecil NF?

A: Official warnings advise that allergic reactions, including severe hypersensitivity (anaphylaxis), may occur. This risk is noted to be particularly relevant for patients with a known history of sensitivity to quinolone medicines.


Q: Is Orecil NF the same class of drug as [Similar Drug Name]?

A: Orecil NF is a combination medicine whose active ingredients belong to three specific classes: a fluoroquinolone antibiotic (Ofloxacin), a corticosteroid (Hydrocortisone), and a local anesthetic (Lidocaine).


Q: Are there any rare but serious side effects of Orecil NF?

A: Official safety information contains a description of rare but serious adverse reactions, including severe hypersensitivity reactions. The systemic form of the antibiotic component also carries warnings related to potential tendon issues.


Q: Can Orecil NF cause stomach upset?

A: Gastrointestinal issues, like stomach upset, are known side effects associated with the systemic use of the Ofloxacin component. However, these effects are reported much more rarely with the local otic solution.


Q: Do I need any special monitoring (like blood tests) while on Orecil NF?

A: Regulatory documents do not typically specify a need for special monitoring, such as routine blood tests, during the use of this localized otic solution. This is due to the low level of systemic absorption of the active ingredients.


Q: Does Orecil NF have a 'black box' warning from the FDA?

A: Official FDA labeling indicates that the most serious safety warnings (Black Box Warnings) associated with systemic (oral or injectable) fluoroquinolone antibiotics do not apply to this localized otic solution.


Q: Can Orecil NF be taken while breastfeeding?

A: Official regulatory information suggests that the maternal use of otic drops presents a negligible risk to the nursing infant. This is because the medicine is applied locally, resulting in minimal systemic absorption by the mother.


Q: Are there any known interactions between Orecil NF and caffeine?

A: Regulatory documents generally do not list a known interaction between this localized otic solution and caffeine.


Q: Can taking Orecil NF cause sensitivity to the sun?

A: Official safety information for the systemic fluoroquinolone class notes the potential for increased skin sensitivity to the sun (photosensitivity). Although this is a localized drop, patients should be aware of this potential class effect.


Q: What are the official contraindications listed for Orecil NF?

A: Official labeling typically states that the solution is contraindicated in patients with a history of hypersensitivity (allergic reaction) to Ofloxacin, other quinolones, or any other component of the formulation.


Q: What happens if I take Orecil NF while pregnant?

A: Ofloxacin, one of the active ingredients, is described in official documentation as Pregnancy Category C by the FDA. This means animal studies have shown a potential risk, but there is no sufficient data from controlled studies in human women.


Q: Are there different strengths of Orecil NF available?

A: Regulatory documents generally list the available strengths and dosage forms of the product as part of the official labeling information.


Q: Is Orecil NF a narcotic or controlled substance?

A: The active ingredients in this solution are not classified as controlled substances by regulatory agencies.

How should Orecil NF be stored and disposed of?

How to Store and Dispose of Orecil NF?

The storage and disposal of Orecil NF otic solution must strictly follow regulatory standards to ensure the medicine remains stable and safe.

Storage Requirement Official Instruction
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep away from excess heat, moisture, and light. Do not freeze.
Container Store in the original container, keeping the bottle tightly closed.
Child Safety Keep Orecil NF out of the sight and reach of children.
Stability Discard any remaining solution after the labeled in-use period following the first opening.

Disposal Instructions

Official guidelines state that Orecil NF must not be disposed of in wastewater (e.g., toilet or drain) or household trash. Unused or expired medicine must be discarded in accordance with local pharmaceutical waste disposal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Orecil NF found in:

A-Z Index: